{"name":"Inimmune Corporation","slug":"inimmune-corporation","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPVWlhZTF3WHcwOWE5dGxjak5uQXBDN3FGSm9SaXkxaG1NdjYxQllQUjFaYkRpMXYtLTdZaHc3Wlk5TV9WbTBxS3VxUjNUOFJ2bkNybDZEb0dTRC0xYzV3eE1nZk1QNV8zcXplU0VVNG85UzEyT3BzaExnajltQVVFd1FNX0Q2X2lCODlXSGhnY1JDcE0?oc=5","date":"2026-04-08","type":"pipeline","source":"openPR.com","summary":"Top Companies and Competitive Dynamics in the Allergy Immunotherapy Market - openPR.com","headline":"Top Companies and Competitive Dynamics in the Allergy Immunotherapy Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxQXzhIcENrYi1mYnB3QWMxWWJxT1NTUExQS2VBSzlrVkN2ZnFtVUhTQklCZmRaeVIxRkliUm1UZ0pvS3gyM3pJNDRaRDBDcElrZlpTX3hNdnd4cnpVSk9GZGVkRk9ORTAxSjNhVW9uUXo0eW1CM2IwZHhZdXdZSFNOSjdZZXVfb0lrY2ZCei1pTGQ3b08xM3dzUW9rUlpQQTF4dS1tT21udHBOSDdYNm1fV3VUd1dhSTd4NzRmSDUyNDQwQ3AzRUFJcFFjbFp2S3NUcUtNVjQ5anBmN0dOblZkZE9hQWJCUjlwUnJKZGhkT0IxRXJ5a3NCdlpLMUU?oc=5","date":"2026-03-12","type":"trial","source":"prnewswire.com","summary":"Inimmune Completes Enrollment and Doses First Patient in Phase 2 Chamber Trial of INI-2004 for Allergic Rhinitis - prnewswire.com","headline":"Inimmune Completes Enrollment and Doses First Patient in Phase 2 Chamber Trial of INI-2004 for Allergic Rhinitis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE95TGduZEI3Sl9La1p6dkp2NFdKQ192aXJNeW0xN3BIRDRJMjlsRGw5RHhaQXY5Z1FjbG5GSjdXV05hTU9jclEyWlA2TE9HZjdIczRhY1I2bWVtRFZabEFNcVh3?oc=5","date":"2026-03-06","type":"pipeline","source":"Missoula Current","summary":"Missoula-based Inimmune names CMO, head of financial strategy - Missoula Current","headline":"Missoula-based Inimmune names CMO, head of financial strategy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNQ3dQeTlxQWdLeGtHS2hiS0hRSkUtTG55M2FmamdQZkdnYXpaLTFYX3dfVEZyaU5ubUpwZC1Da21aVExNZ18xVkVwMnlUZ2V3TzZtbE5wdm1ndzJCbzlVSG9ycUZVOXg2T1lnUS01QlhOSjdYeUVwY3BxY3JHRUNJY3EzUC1OT05aa1lDUTdlNkFWUQ?oc=5","date":"2026-03-05","type":"trial","source":"Yahoo Finance","summary":"Inimmune Strengthens Leadership Team Ahead of Phase 2 INI-2004 Allergic Rhinitis Data Readout - Yahoo Finance","headline":"Inimmune Strengthens Leadership Team Ahead of Phase 2 INI-2004 Allergic Rhinitis Data Readout","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTE0zUlBTOGxpeTR5eHJCdWprZWZPTTFCeUdiS3RZUXRQN1RRekZwODRwNzhEWlRySzFTVXdqLVJXV1hKRmZGeEh6MG5DMl9xTndTUUxwbkhSbmd6MHJVVHBuejAzOA?oc=5","date":"2026-01-28","type":"pipeline","source":"The Jerusalem Post","summary":"Israeli AI breakthrough in immune system mapping - The Jerusalem Post","headline":"Israeli AI breakthrough in immune system mapping","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE94RzZZRGdJOVJ5MktMQ1VwU2cteW5xZV9LOWIxUzRvUlZLb1RwM2Z0WV82UVBBX05pUi1EWGxybFpxTUYtU0xuNElZTDloc25aYUN0cmNJbjA2UUdOWHdn?oc=5","date":"2026-01-13","type":"trial","source":"Nature","summary":"Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial - Nature","headline":"Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxPSkJHVkp1OENhMjVlNnlXelNQN2R5S3EzRFZTbmJRd3pLTWxNRnUxVGgwN2toa2Fuc2xXS181WFlZX21SeGxORWJCc0NONDJBbm43b2cyN0pHTURBT1hNUkowby13MWpMNkV0MHBnbERWNDNVclNlNjdzQ2FPbHRnSnFJQkxzSW13a3d0REtB?oc=5","date":"2026-01-05","type":"trial","source":"BioPharma Dive","summary":"Zenas shares crash after top drug misses expectations in immune disease study - BioPharma Dive","headline":"Zenas shares crash after top drug misses expectations in immune disease study","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPMlBzRnJxcm9pdjJYdGZUeFdQcTY3ejVYZ2tEUlJrZWFFMEFIdEJ1eURxSk1mc2UtaHdxd3UyOHIwcXdob01vNDNEUjAxMFF2M0xCelhuVFp0bEp5SjRGd1lWYnFFYlRJMWNBbGlHWEVwaW5INFppbXB1d2E5S0hBTUJDVXVKTVpYdms1UUt3SHVMaV8tNzBIRzhqdVd0cTJHeW1QYlBHUnE5Q19abUtvNGN6SUZ0ajkzVzgxQ1ZR?oc=5","date":"2025-10-28","type":"trial","source":"Fierce Pharma","summary":"After lupus nephritis nod, Roche keeps Gazyva momentum rolling with phase 3 win in another kidney condition - Fierce Pharma","headline":"After lupus nephritis nod, Roche keeps Gazyva momentum rolling with phase 3 win in another kidney condition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQakNOOWhCdUkwczUxU2IxTEFXTnBYQ3dkQncwazNGX1F2S3JoZmhERHZnUzRDekJpeGVxU3JLTmFCRXQyYUJnaHRRVENWdkZXSnUxSTIwcmhBZzBOeWd2WlZneWdaVFFDNS11dUFGS1VSaWpWb3QyS3d3T2xvWlktMjhCNGEwZUdEOXc3eDE0SHRVa0NGUmFVV0Vzb2RWeFE?oc=5","date":"2024-09-19","type":"pipeline","source":"Rockefeller University Press","summary":"Targeting TNF/TNFR superfamilies in immune-mediated inflammatory diseases | Journal of Experimental Medicine - Rockefeller University Press","headline":"Targeting TNF/TNFR superfamilies in immune-mediated inflammatory diseases | Journal of Experimental Medicine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxQVE83MVgyNUx0OVJISnJrVnJUMFpva2xqY0Q1dVNrcm9WV3RhdGwyd2trZDZxZU1HQllnNDBidWVGWVMtdU44QnhTMkRRblRpTHRZMlo3MVA3aE14UGw1LVB6cDBRaGJXbTQ4ZW5kdHhzY29nTjZhS3pZbEIzY3VvUWRBY2cyYWMxZFdQd1pYcFVHUXdka2czUlBnUkNDb1RzM09DS0pac01wMFFxcW5WTjIyTTVmSUkyRDdSbHhranFNcGZLalkxQjc2TXJ0LU1tQ3ZFRlNzNk44QUw3aWEwWlJOazdzeW9ybkNIMUJIbVlnZzA?oc=5","date":"2024-07-16","type":"deal","source":"prnewswire.com","summary":"SPI Pharma, Inc. and Inimmune, Corp. Partner to Develop and Commercialize Innovative Vaccine Adjuvant Systems - prnewswire.com","headline":"SPI Pharma, Inc. and Inimmune, Corp. Partner to Develop and Commercialize Innovative Vaccine Adjuvant Systems","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNS01wSWd0RXFnMkVFcXExNlpGTjlhemtXOWp0ZDV1WEoxOURhMk4teWdOMmw0RjZpem12TjM1NUdGQ2h1djdhMXpUa3R4RzdES1o2S1Y5cUtaZEp0TnJTLTh3UjYwSDBjR0VuRjhLRzZWTGRfR2NRTkhjaFV3dmZjMU9hcHNEeWQ5c1JxZnI0ZTlSX0s3THc4c0xXMXA0SEJPSnY1eTVoaVlFYTBxM1RQZkNoVFAyTzd1bi1hMA?oc=5","date":"2022-11-02","type":"pipeline","source":"Boston Consulting Group","summary":"Improving Care in Immune-Mediated Diseases | BCG - Boston Consulting Group","headline":"Improving Care in Immune-Mediated Diseases | BCG","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxOZ2E3a3YybWZ6cnZfZ2Rpa2FhcXdCTWlxS2xpSHQ4bGZhRnFpRXhrVmpHY2JLcHRZenE2QllyNnJhTE9xMGNva2gwbUFnenpGUWlJcHNGNlpMOWlidzZ0blpodldhNTRjLUVpZEs3WTNJMlo1Wkd0V2Q1a1cyeGxIeFQzQ0oxUUpLRjQydHA5VmdvRUFkUGNoNFJTZ3ItQWE0WmRJeDZBLVY3emZSNHR2N2lJR3FzX3FIbUk1WmR5QlFtSWllRTZEM3ZENEJDQWVaeXd2RA?oc=5","date":"2022-06-13","type":"pipeline","source":"BioSpace","summary":"META Pharmaceuticals, a pioneer biotech in immune-metabolism, raised 15M USD to accelerate its pipeline development - BioSpace","headline":"META Pharmaceuticals, a pioneer biotech in immune-metabolism, raised 15M USD to accelerate its pipeline development","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}